DGIdb - PROGESTERONE Drug Record

PROGESTERONE chembl:CHEMBL103 Approved

Alternate Names:

NSC-64377
CRINONE
PROGESTA-CARE
PROGESTASERT
PROCHIEVE
GESTEROL
REGUMATE
U 3672
NSC-9704
SYNGESTRONE
SERENITY FOR WOMEN
PROGESTIN
CYCLOGEST
UTROGESTAN
PROGESTERONE
LUTIGEST
ENDOMETRIN
PROMETRIUM
PROGEFFIK
FOLOGENON
PREGN-4-ENE-3,20-DIONE
CORLUVITE
GESTORMONE
LUTROMONE
LUTOCUCLIN M
LUTEOCRIN NORMALE
GELBKÖRPERHORMON
(S)-PREGN-4-EN-3,20-DIONE
GESTEROL 50
PROGESTÉRONE
PROGESTOL
4-PREGNENE-3,20-DIONE
LUTEOPUR
PROGESTOGEL
PROLUTON
GESTRON
PREGNENE-3,20-DIONE
PROMETRIUM®
PROTORMONE
PIAPONON
DELTA(4)-PREGNENE-3,20-DIONE
PROGESTERON
GESTONE
LUCORTEUM
LUTOCYCLIN M
LINGUSORBS
CORPORIN
PERCUTACRINE LUTEINIQUE
LUTOGYL
NALUTRON
LUTIDON
LUTEAL HORMONE
CORPUS LUTEUM HORMONE
LUTEOSAN
CIDR
17A-PROGESTERONE
LUTEOHORMONE
LUTOGYNON
(1S,2R,10S,11S,14S,15S)-14-ACETYL-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
SYNGESTRETS
LUTEOSTAB
PROGESTAN
VITARRINE
MEMBRETTES
(8S,9S,10R,13S,14S,17S)-17-ETHANOYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
LUTEOL
CYCLOGESTERIN
UTROGESTAN®
LUTEOGAN
LUTOCICLINA
LUTEUM
PROGESTEROL
4-PREGNEN-3,20-DIONE
GLANDUCORPIN
LUTREN
LUTOCYLOL
GYNOLUTON
BIO-LUTON
PREGN-4-EN-3,20-DIONE
PRONTOGEST
AGOLUTIN
PROGESTRONOL
PROLUTIN
PROGESTERONA
PROGEKAN
SYNTOLUTAN
DELTA(SUP 4)-PREGNENE-3,20-DIONE
D4-PREGNENE-3,20-DIONE
(8S,9S,10R,13S,14S,17S)-17-ACETYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
SYNOVEX S
17Α-PROGESTERONE
CRINONE PROGESTERONE GEL
PERCUTACRINE
LIPO-LUTIN
FLAVOLUTAN
PROGESTON
LUTOCYLIN
LUTOFORM
LUCORTEUM SOL
PROGESTONE
GESTIRON
LUTEOVIS
(S)-4-PREGNENE-3,20-DIONE
SYNGESTERONE
ESTIMA
17ALPHA-PROGESTERONE
PROLIDON
UTROGEST
LUTEODYN
DELALUTIN
PRIMOLUT
AKROLUTIN
DURAPROGEN
(S)-PROGESTERONE
CURRETAB
GYNOLUTONE
BETA-PROGESTERONE
LUTEX
PROGESTERONUM
MPA
HORMOFLAVEINE
PRANONE
PREGNENEDIONE
HORMOLUTON
PROGESTOSOL
GYNLUTIN
PROGESTRON
LUTOCYCLIN
LUGESTERON
CORLUTINA
3,20-PREGNENE-4
PROJESTAJECT
METHYLPREGNONE
COLPROSTERONE
CORLUTIN
PROLUTONE
PROLETS
GESTEROL 100
pubchem.compound:5994
chemidplus:57-83-0
rxcui:8727
chembl:CHEMBL103
drugbank:00396

Drug Info:

FDA Approval	approved
Drug Class	small molecule
Drug Indications	contraceptive
Drug Indications	for reducing the risk of pre-term birth for women with short cervix a mid-pregnancy
Drug Indications	for prevention of preterm delivery
Drug Indications	for symptomatic treatment of menopausal symptoms
Drug Indications	neuroprotectant for stroke victims
Year of Approval	approved before 1982
Drug Class	contraceptives

(8 More Sources)

Publications:

Rupprecht et al., 1993, Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands., Eur. J. Pharmacol.
Souque A et al., 1995, The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent., Endocrinology
Quinkler M et al., 2002, Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor., Eur J Endocrinol
Myles K et al., 1996, Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies., Am J Physiol
Takagi et al., 2002, Bovine retained placenta: hormonal concentrations in fetal and maternal placenta., Placenta
King et al., 2003, Differential regulation of secretory leukocyte protease inhibitor and elafin by progesterone., Biochem. Biophys. Res. Commun.
Barten et al., 2003, Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood., J. Immunol. Methods
Mitchell et al., 2002, Differential expression of activator protein-1 transcription factors in pregnant rat myometrium., Biol. Reprod.
Vicent et al., 1998, Influence of calf serum on glucocorticoid-responses of certain progesterone derivatives., J. Steroid Biochem. Mol. Biol.
Nakamura et al., 2001, Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil., Clin Transplant
Labriola et al., 2003, Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells., Mol. Cell. Biol.
Balañá et al., 1999, Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas., Oncogene
Zagrodzki et al., 2007, The interaction between selenium status, sex hormones, and thyroid metabolism in adolescent girls in the luteal phase of their menstrual cycle., Biol Trace Elem Res
Luconi et al., 1998, Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane., J. Clin. Endocrinol. Metab.
Boonyaratanakornkit et al., 2007, The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle., Mol. Endocrinol.
Gizard et al., 2006, TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone., Mol. Cell. Biol.
Madauss et al., 2007, The evolution of progesterone receptor ligands., Med Res Rev
Tranguch et al., 2006, Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation., Reprod. Biomed. Online
Wu et al., 2006, Progesterone receptors activation after acute cocaine administration., Brain Res.
Alvarez LD et al., 2011, Biological activity and ligand binding mode to the progesterone receptor of A-homo analogues of progesterone., Bioorg Med Chem
Okada H et al., 2018, Decidualization of the human endometrium., Reprod Med Biol
Ackland et al., 1997, Expression of Menkes disease gene in mammary carcinoma cells., Biochem. J.
Seiler et al., 1995, Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist., Biochem. Pharmacol.
Tosca et al., 2005, Adenosine 5'-monophosphate-activated protein kinase regulates progesterone secretion in rat granulosa cells., Endocrinology
Zarghami et al., 1997, Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer., Br. J. Cancer
Bentel JM et al., 1999, Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells., Mol Cell Endocrinol
Yuan X et al., 2009, Mechanisms mediating androgen receptor reactivation after castration., Urol Oncol
Miedema BW et al., 1992, Human gastric and jejunal transit and motility after Roux gastrojejunostomy., Gastroenterology
Kumar et al., 2007, Type and duration of exogenous hormone use affects breast cancer histology., Ann. Surg. Oncol.
Montero Girard et al., 2007, Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment., Breast Cancer Res.
Yuri et al., Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats., In Vivo
Lessey et al., 2006, Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women., Reprod. Biol. Endocrinol.
Ghebeh et al., 2007, Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells., Int. J. Cancer
Jayaraman A et al., 2009, Progesterone attenuates oestrogen neuroprotection via downregulation of oestrogen receptor expression in cultured neurones., J Neuroendocrinol
Mohammed H et al., 2015, Progesterone receptor modulates ERα action in breast cancer., Nature
Tessier C et al., 2000, Estrogen receptors alpha and beta in rat decidua cells: cell-specific expression and differential regulation by steroid hormones and prolactin., Endocrinology
Désarnaud et al., 1998, Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells., J. Neurochem.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Zubiaur P et al., 2019, Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally., Adv Ther
Musgrove et al., 2001, Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2., J. Biol. Chem.
Swarbrick et al., 2000, Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells., Mol. Cell. Biol.
Medina et al., 2004, Differential regulation of glucose transporter expression by estrogen and progesterone in Ishikawa endometrial cancer cells., J. Endocrinol.
Stickeler et al., Modulation of soluble CD44 concentrations by hormone and anti-hormone treatment in gynecological tumor cell lines., Oncol. Rep.
Saitoh et al., 2005, Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells., Endocrinology
Fu et al., 2008, Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton., PLoS ONE
Kimura et al., 1991, The biological effects of macrophage-colony-stimulating factor induced by progestin on growth and differentiation of endometrial adenocarcinoma cells., Int. J. Cancer
Prost-Avallet et al., 1991, In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma., J. Steroid Biochem. Mol. Biol.
Kang et al., 1996, Suppression of plasma estradiol and progesterone concentrations by buthionine sulfoximine in female rats., Biochem. Pharmacol.
Kaur et al., 2007, Progesterone increases brain-derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants., J. Neurosci. Res.
Adişen et al., 2006, The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis., J Eur Acad Dermatol Venereol
Khurana et al., 1993, Receptor-mediated stimulatory effect of atrial natriuretic factor, brain natriuretic peptide, and C-type natriuretic peptide on testosterone production in purified mouse Leydig cells: activation of cholesterol side-chain cleavage enzyme., Endocrinology
Dorey et al., 1999, Regulation of human c-Abl tyrosine kinase activity in Xenopus oocytes and acceleration of progesterone-induced G2/M transition by oncogenic forms., Biol. Chem.
Salatino et al., 2006, Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation., Oncogene
Wu et al., 2005, Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells., Mol. Endocrinol.
Cui et al., 2003, Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2., Oncogene
McBean et al., 1997, In vivo estrogen regulation of epidermal growth factor receptor in human endometrium., J. Clin. Endocrinol. Metab.
Attanasio et al., 2002, Immunomodulatory effects of estrogen and progesterone replacement in a nonhuman primate model., J. Clin. Immunol.
Rodríguez-Cuenca et al., 2007, Expression of mitochondrial biogenesis-signaling factors in brown adipocytes is influenced specifically by 17beta-estradiol, testosterone, and progesterone., Am. J. Physiol. Endocrinol. Metab.
Aoki et al., 2003, Effects of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells., J. Steroid Biochem. Mol. Biol.
Syed et al., 2005, Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling., Oncogene
Silberstein et al., 2002, Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth., Oncogene
Melcangi et al., 1997, Astrocyte-neuron interactions in vitro: role of growth factors and steroids on LHRH dynamics., Brain Res. Bull.
Ordi et al., 2006, Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation., Am. J. Reprod. Immunol.
Schutzer et al., 1997, Lack of ovarian steroid hormone regulation of norepinephrine transporter mRNA expression in the non-human primate locus coeruleus., Psychoneuroendocrinology
Guzeloglu-Kayisli et al., 2003, Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium., J. Clin. Endocrinol. Metab.
Ordóñez et al., 2007, Insulin sensitivity in streptozotocin-induced diabetic rats treated with different doses of 17beta-oestradiol or progesterone., Exp. Physiol.
Aydin et al., 1998, Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy., J Chemother
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Fujimoto et al., 1996, Requirement for transglutaminase in progesterone-induced decidualization of human endometrial stromal cells., Endocrinology
Lima et al., 2008, Unique responses of midbrain CART neurons in macaques to ovarian steroids., Brain Res.
Holst et al., 1983, Percutaneous oestrogen therapy opposed by lynestrenol or natural progesterone--effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein., Maturitas
Dexheimer TS et al., 2009, 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors., J Med Chem
Leo JC et al., 2004, Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells., Endocrinology
Xu XF et al., 1990, Progestin binds to the glucocorticoid receptor and mediates antiglucocorticoid effect in rat adipose precursor cells., J Steroid Biochem
Attardi et al., 2007, Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins., Am. J. Obstet. Gynecol.
Strickler et al., 1982, 20 alpha-Hydroxysteroid dehydrogenase and 17 beta-estradiol dehydrogenase localize in cytosol of human term placenta., Am. J. Physiol.
de la Llosa-Hermier et al., 1983, Inhibitory effect of ovine and human placental lactogens on progesterone catabolism in luteinized rat ovaries in vitro., Placenta
Jones et al., 1982, Regulation of ovarian progestin production by epidermal growth factor in cultured rat granulosa cells., J. Biol. Chem.
Rabe et al., 1985, Regulation of human placental progesterone synthesis in vitro by naturally occurring steroids., J. Steroid Biochem.
Fukuda et al., 1986, Microsomal 20 alpha-hydroxysteroid dehydrogenase activity for progesterone in human placenta., Endocrinol. Jpn.
Tsang et al., 1989, Influence of A23187 and dibutyryl cyclic AMP on progestagen production by rat granulosa cells in vitro., J. Reprod. Fertil.
Wu et al., 1976, Luteotropic regulation of dispersed rat luteal cells in early pregnancy., Endocrinology
Higaki et al., 2003, Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone., Chem. Biol. Interact.

PROGESTERONE PAX2

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11850818

Sources:
NCI
PROGESTERONE ATF3

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15674352

Sources:
NCI
PROGESTERONE CR2

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9141535

Sources:
NCI
PROGESTERONE CTSC

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17916955

Sources:
NCI
PROGESTERONE PI3

Interaction Score: 1.85

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14521952

Sources:
NCI
PROGESTERONE AKR1C1

Interaction Score: 1.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6950669 6584862 6288675 3859707 3463506 2547059 179793 12604236

Sources:
NCI
PROGESTERONE PMP22

Interaction Score: 0.92

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9751213

Sources:
NCI
PROGESTERONE RNASEH2A

Interaction Score: 0.92

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12080023

Sources:
NCI
PROGESTERONE EPHB1

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9279938

Sources:
NCI
PROGESTERONE CD44

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11605071

Sources:
NCI
PROGESTERONE NME2

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15674352

Sources:
NCI
PROGESTERONE PZP

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6410156

Sources:
NCI
PROGESTERONE CARTPT

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18598674

Sources:
NCI
PROGESTERONE PRKAB1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16020477

Sources:
NCI
PROGESTERONE TYMP

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12711006

Sources:
NCI
PROGESTERONE ATP7A

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9359859

Sources:
NCI
PROGESTERONE CD28

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11903384

Sources:
NCI
PROGESTERONE NR3C2

Interaction Score: 0.26

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name BHR-100

Novel drug target Established target

Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

PMIDs:
8282004 7588320 12039699 8928765

Sources:
TdgClinicalTrial
PROGESTERONE PGR

Interaction Score: 0.24

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name BHR-100

Novel drug target Established target

Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

PMIDs:
9506743 17138644 17015480 17013809 17169175 17109827 21315613 30013421

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND TTD
PROGESTERONE TPM3

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549730

Sources:
NCI
PROGESTERONE STS

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1751397

Sources:
NCI
PROGESTERONE TAT

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9744518

Sources:
NCI
PROGESTERONE NPPC

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8404664

Sources:
NCI
PROGESTERONE SLC2A1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15350188

Sources:
NCI
PROGESTERONE PROS1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Estradiol,Progesterone

PMIDs:
None found

Sources:
FDA
PROGESTERONE CDKN1B

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11590147

Sources:
NCI
PROGESTERONE OXTR

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12061859

Sources:
NCI
PROGESTERONE CP

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8619904

Sources:
NCI
PROGESTERONE PROC

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Estradiol,Progesterone

PMIDs:
None found

Sources:
FDA
PROGESTERONE NRG1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12529413 10597237

Sources:
NCI
PROGESTERONE KLK3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9052414

Sources:
NCI
PROGESTERONE FCGR3B

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16635211

Sources:
NCI
PROGESTERONE FAS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14659903

Sources:
NCI
PROGESTERONE CCND1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16123159

Sources:
NCI
PROGESTERONE TGM2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8603579

Sources:
NCI
PROGESTERONE PLA2G1B

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7872957

Sources:
NCI
PROGESTERONE GFAP

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9370212

Sources:
NCI
PROGESTERONE IL2RA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12405159

Sources:
NCI
PROGESTERONE CDK4

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10713180

Sources:
NCI
PROGESTERONE ROCK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18665217

Sources:
NCI
PROGESTERONE ESR1

Interaction Score: 0.05

Interaction Types & Directionality:

negative modulator (inhibitory)

agonist (activating)

inhibitor (inhibitory)

Interaction Info:

Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

Novel drug target Established target

Trial Name BHR-100

PMIDs:
17103262 17341305 17203775 17118173 17415709 19094096 26153859 11014241

Sources:
TdgClinicalTrial TEND
PROGESTERONE CSF2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9822358

Sources:
NCI
PROGESTERONE SLC2A4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17068109

Sources:
NCI
PROGESTERONE PIK3CG

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16799639 15528272 14534541

Sources:
NCI
PROGESTERONE SERPINC1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Estradiol,Progesterone

PMIDs:
None found

Sources:
FDA
PROGESTERONE CSF1R

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1831804

Sources:
NCI
PROGESTERONE PIK3CB

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16954335

Sources:
NCI
PROGESTERONE TDP1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19883083

Sources:
DTC
PROGESTERONE NR3C1

Interaction Score: 0.03

Interaction Types & Directionality:

partial agonist (activating)

Interaction Info:

PMIDs:
14617569 2214763 18060946

Sources:
DTC
PROGESTERONE ABL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10195429

Sources:
NCI
PROGESTERONE PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14557489

Sources:
NCI
PROGESTERONE CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
PROGESTERONE RXRA

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROGESTERONE RORC

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROGESTERONE NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PROGESTERONE TARDBP

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROGESTERONE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 31482508

Sources:
DTC PharmGKB
PROGESTERONE MAPK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROGESTERONE TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16684279

Sources:
NCI
PROGESTERONE CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PROGESTERONE AR

Interaction Score: 0.0

Interaction Types & Directionality:

agonist (activating)

potentiator

Interaction Info:

PMIDs:
10509795 19111796 1397870

Sources:
DTC
PROGESTERONE ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PROGESTERONE CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PROGESTERONE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PROGESTERONE ALDH1A1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PROGESTERONE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
PROGESTERONE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: PROGESTERONE
- Version: 01-August-2011
Alternate Names:

PROGESTERONE Primary Drug Name

Drug Info:

Drug Class contraceptives

Year of Approval approved before 1982

Publications:
TdgClinicalTrial: PROGESTIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications contraceptive

Drug Class small molecule

FDA Approval approved

Publications:
TdgClinicalTrial: PROGESTERONE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications neuroprotectant for stroke victims

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: PROGESTERONE

Version: 14-September-2017

Alternate Names:

C777 NCI drug code

Drug Info:

Publications:

Takagi et al., 2002, Bovine retained placenta: hormonal concentrations in fetal and maternal placenta., Placenta

Mitchell et al., 2002, Differential expression of activator protein-1 transcription factors in pregnant rat myometrium., Biol. Reprod.

Vicent et al., 1998, Influence of calf serum on glucocorticoid-responses of certain progesterone derivatives., J. Steroid Biochem. Mol. Biol.

NCI: PROGESTIN

Version: 14-September-2017

Alternate Names:

C777 NCI drug code

Drug Info:

Publications:

Kimura et al., 1991, The biological effects of macrophage-colony-stimulating factor induced by progestin on growth and differentiation of endometrial adenocarcinoma cells., Int. J. Cancer

Musgrove et al., 2001, Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2., J. Biol. Chem.

Ordi et al., 2006, Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation., Am. J. Reprod. Immunol.

NCI: MPA

Version: 14-September-2017

Alternate Names:

C1155 NCI drug code

C673 NCI drug code

Drug Info:

Publications:

Seiler et al., 1995, Inhibition of thrombin and SFLLR-peptide stimulation of platelet aggregation, phospholipase A2 and Na+/H+ exchange by a thrombin receptor antagonist., Biochem. Pharmacol.

Nakamura et al., 2001, Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil., Clin Transplant

Aydin et al., 1998, Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy., J Chemother

DTC: PROGESTERONE

Version: 02-September-2020

Alternate Names:

CHEMBL103 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Dexheimer TS et al., 2009, 4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors., J Med Chem

Alvarez LD et al., 2011, Biological activity and ligand binding mode to the progesterone receptor of A-homo analogues of progesterone., Bioorg Med Chem

PharmGKB: progesterone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Zubiaur P et al., 2019, Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally., Adv Ther

TTD: Progesterone
- Version: 2020.06.01
Alternate Names:

D07BSQ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL103
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Progesterone
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL103
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	BHR-100
Novel drug target	Established target
Trial Name	conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

agonist (activating)
antagonist (inhibitory)

PROGESTERONE Drug Record

PROGESTERONE chembl:CHEMBL103 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11850818

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15674352

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9141535

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17916955

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14521952

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6950669 6584862 6288675 3859707 3463506 2547059 179793 12604236

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9751213

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12080023

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9279938

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11605071

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15674352

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6410156

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18598674

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16020477

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12711006

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9359859

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11903384

Sources: NCI

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Trial Name BHR-100 Novel drug target Established target Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

PMIDs: 8282004 7588320 12039699 8928765

Sources: TdgClinicalTrial

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name BHR-100 Novel drug target Established target Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

PMIDs: 9506743 17138644 17015480 17013809 17169175 17109827 21315613 30013421

Interaction Types & Directionality:

n/a

PMIDs:
11850818

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15674352

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9141535

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17916955

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14521952

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6950669 6584862 6288675 3859707 3463506 2547059 179793 12604236

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9751213

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12080023

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9279938

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11605071

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15674352

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6410156

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18598674

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16020477

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12711006

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9359859

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11903384

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name BHR-100

Novel drug target Established target

Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

PMIDs:
8282004 7588320 12039699 8928765

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name BHR-100

Novel drug target Established target

Trial Name conjugated estrogens/medroxyprogesterone acetate,Prempro, Premphase

PMIDs:
9506743 17138644 17015480 17013809 17169175 17109827 21315613 30013421

Sources:
DTC TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
17549730

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1751397

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9744518

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8404664

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15350188

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Combination therapy Estradiol,Progesterone

PMIDs:
None found

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
11590147